Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CEA-specific CAR-NK cells
- Development stage
- Preclinical
- Lead developer
- Candiolo Cancer Institute
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CEA-specific CAR-NK cells are an investigational chimeric antigen receptor (CAR) natural killer (NK) cell therapy targeting carcinoembryonic antigen (CEA), a glycoprotein overexpressed in colorectal cancer (CRC) and other solid tumors. The therapy involves engineering NK cells—either the NK-92 cell line or induced pluripotent stem cell (iPSC)-derived NK cells (iNKs)—to express a second-generation CAR, typically utilizing the high-affinity hMN-14 scFv. These cells may be further enhanced through cytokine engineering, such as the constitutive expression of interleukins, to boost their anti-tumor activity and persistence. Preclinical studies have demonstrated that these CAR-NK cells effectively reduce tumor progression in CEA-positive CRC xenograft models, presenting a potentially safer and more scalable alternative to CAR-T cell therapies.
- Other names
- CEA-CAR-NK-92CEA-CAR-NK92CEA-CAR-NK 92CEA-CAR-iNKCEA-specific CAR-NK-92 cellsCEA-specific CAR-iNK cells
02
Targets
CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)
Beyond the preview
Go deeper on CEA-specific CAR-NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CEA-specific CAR-NK cells.